AbbVie and Genmab Report Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Relapsed/Refractory DLBCL
New drug combo helps lymphoma patients live longer without worsening disease, cutting risk by ~60%—without chemotherapy.
/ 11 items
#ABBV↓
AbbVie Bolsters Immunology Pipeline with $10.9 Billion Apogee Acquisition
The acquisition would add a longer-acting alternative to Dupixent for inflammatory diseases.
AbbVie Beats 2026 Profit Forecast Despite Market Concerns Over Drug Portfolio Mix
AbbVie (ABBV) reports strong Q4 earnings and raises 2026 profit outlook to $14.37-$14.57 per share, beating Wall Street estimates, though investors worry about Humira decline and aesthetics challenges.
Merck Ends Talks to Buy Cancer Biotech Revolution Medicines in $30B Deal
Merck has walked away from negotiations to acquire Revolution Medicines after failing to agree on price for the promising cancer drug developer valued around $30 billion.
AbbVie Denies Acquisition Talks with Revolution Medicines Despite WSJ Report
AbbVie denies reports of buying Revolution Medicines after Wall Street Journal claimed advanced talks.
LENZ Stock Plunges After Retinal Tear Case Linked to VIZZ Eye Drops
LENZ Therapeutics shares dropped 27% following reports of a retinal tear associated with VIZZ presbyopia treatment, raising investor safety concerns despite company reassurances.